Abbott Laboratories Stock

Equities

ABT

US0028241000

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:02 2024-04-23 pm EDT 5-day change 1st Jan Change
107.6 USD +0.49% Intraday chart for Abbott Laboratories -1.48% -2.25%
Sales 2024 * 41.7B Sales 2025 * 44.75B Capitalization 187B
Net income 2024 * 5.96B Net income 2025 * 7.17B EV / Sales 2024 * 4.61 x
Net Debt 2024 * 5.47B Net cash position 2025 * 913M EV / Sales 2025 * 4.15 x
P/E ratio 2024 *
31.4 x
P/E ratio 2025 *
26.8 x
Employees 114,000
Yield 2024 *
2.01%
Yield 2025 *
2.15%
Free-Float 86.77%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.49%
1 week-1.48%
Current month-5.34%
1 month-2.70%
3 months-5.62%
6 months+12.33%
Current year-2.25%
More quotes
1 week
104.47
Extreme 104.47
108.11
1 month
104.25
Extreme 104.25
114.02
Current year
104.25
Extreme 104.25
121.64
1 year
89.67
Extreme 89.674
121.64
3 years
89.67
Extreme 89.674
142.60
5 years
61.61
Extreme 61.61
142.60
10 years
36.00
Extreme 36
142.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 14-12-31
Director of Finance/CFO 51 96-12-31
Chief Tech/Sci/R&D Officer - 89-12-31
Members of the board TitleAgeSince
Director/Board Member 69 17-02-15
Director/Board Member 63 17-06-28
Director/Board Member 65 11-12-08
More insiders
Date Price Change Volume
24-04-23 107.6 +0.49% 3,849,589
24-04-22 107.1 -0.20% 4,948,315
24-04-19 107.3 +1.91% 10,533,616
24-04-18 105.3 -0.59% 7,306,449
24-04-17 105.9 -3.03% 12,002,886

Delayed Quote Nyse, April 23, 2024 at 04:00 pm EDT

More quotes
Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows: - diagnostic systems and instruments (39.1%); - vascular devices (24.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.; - nutrition products (12.1%): pediatric nutrition products, nutritional supplements, and dietetic products; - medicine (8.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.; - other (15.9%). Net sales are distributed geographically as follows: the United States (38.5%), Germany (5.8%), China (5.6%), India (4.4%), Switzerland (4.1%), Japan (3.8%), Netherlands (2.7%) and others (35.1%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
107.6 USD
Average target price
126.3 USD
Spread / Average Target
+17.42%
Consensus